The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

Adult AD diagnoses were based on the modified ... separate cultures from two separate sites of clinically noninfected atopic skin after administration of the corresponding intervention.

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Later on in the day, confirmation finally came in – Zoryve had been approved as a new, once-daily treatment for mild to moderate atopic dermatitis in adults and children six years of age and ...

Atopic dermatitis (AD) is a skin disease of chronic inflammation exacerbated by acute flares that commonly affects infants, children, and adults. Therapies generally include emollients ...

In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...

The FDA has since approved Cibinqo (abrocitinib) and Rinvoq (upadacitinib) for the treatment of refractory, moderate-to-severe atopic dermatitis in those whose disease is not well controlled with ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...